US4515781A
Expired / Lapsed
US
⏱️ 0.0 years remaining
2',5'-Riboadenylate-morpholinoadenylate nucleotides
Assignee: United States Department of Health and Human Services
•
Filing: 1983-02-23
•
Granted: 1985-05-07
•
Expires: 2003-02-23
Abstract
Abstract Novel nucleotide compounds are afforded, having at least one 2',5'-riboadenylate unit and a terminal morpholinoadenylate unit. These compounds have potentiated biological activity in the 2,5-A system and increased resistance to degradation.
Inventors
- 👤 Paul F. Torrence
- 👤 Margaret I. Johnston
- 👤 Jiro Imai
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 10:42
CPC Classifications
C; C07; C07H; C07H21/00; A; A61; A61P; A61P35/00; A61P37/00; A61P43/00; C07H19/00; C07H19/02; C07H19/04; C07H19/16; C07H19/20
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
88 words
A nucleotide compound with a 2,5-internucleotide linkage having 1 to 15 riboseadenine unit and a terminal morpholine unit, having the formula ##STR5## wherein: Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C 1-20 primary or secondary alcohol; m is 0, 1, 2, 3 or 4; n is an integer from 1 to 15; and Z is H or a C 1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring.
Claim 2
Dependent Claim
88 words
A nucleotide compound with a 2,5-internucleotide linkage having 1 to 15 riboseadenine unit and a terminal morpholine unit, having the formula ##STR5## wherein: Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C 1-20 primary or secondary alcohol; m is 0, 1, 2, 3 or 4; n is an integer from 1 to 15; and Z is H or a C 1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring.
Claim 3
Dependent Claim
11 words
The compound of claim 1 wherein Z has 1-40 C atoms.
Claim 4
Dependent Claim
11 words
The compound of claim 1 wherein Z has 1-30 C atoms.
Claim 5
Dependent Claim
12 words
The compound of claim 1 wherein m is 0, 1 or 3.
Claim 6
Dependent Claim
9 words
The compound of claim 1 wherein Y is H.
Claim 7
Dependent Claim
9 words
The compound of claim 4 wherein Y is H.
Claim 8
Dependent Claim
12 words
The compound of claim 1 wherein n is from 2 to 6.
Claim 9
Dependent Claim
12 words
The compound of claim 7 wherein n is 2, 3 or 4.
Claim 10
Independent Claim
109 words
A method of blocking the action of interferon produced by animal cells comprising using as an antagonist an effective amount of a nucleotide compound with a 2,5-internucleotide linkage having 1 to 15 ribose-adenine unit and a terminal morpholine unit, having the formula ##STR6## wherein: Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C 1-20 primary or secondary alcohol; m is 0, 1, 2, 3 or 4; n is an integer from 1 to 15; and Z is H or a C 1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring.
Claim 11
Independent Claim
109 words
A method of blocking the action of interferon produced by animal cells comprising using as an antagonist an effective amount of a nucleotide compound with a 2,5-internucleotide linkage having 1 to 15 ribose-adenine unit and a terminal morpholine unit, having the formula ##STR6## wherein: Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C 1-20 primary or secondary alcohol; m is 0, 1, 2, 3 or 4; n is an integer from 1 to 15; and Z is H or a C 1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring.
Claim 12
Independent Claim
111 words
A method of treating interferon-induced autoimmune disease comprising administering to a host having said disease a pharmaceutically effective amount of a nucleotide compound with a 2,5-internucleotide linkage having 1-15 ribose-adenine unit and a terminal morpholine unit, having the formula ##STR7## wherein: Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C 1-20 primary or secondary alcohol; m is 0, 1, 2, 3 or 4; n is an integer from 1 to 15; and Z is H or a C 1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring; and a pharmaceutically acceptable carrier.
Claim 13
Independent Claim
111 words
A method of treating interferon-induced autoimmune disease comprising administering to a host having said disease a pharmaceutically effective amount of a nucleotide compound with a 2,5-internucleotide linkage having 1-15 ribose-adenine unit and a terminal morpholine unit, having the formula ##STR7## wherein: Y is always H except on the terminal phosphate where Y may be H, adenosine, or a C 1-20 primary or secondary alcohol; m is 0, 1, 2, 3 or 4; n is an integer from 1 to 15; and Z is H or a C 1-50 hydrocarbon or substituted hydrocarbon bonded through one of its C atoms to the N of the morpholino ring; and a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US3532695A
Cited
US3542776A
Cited
US3687808A
Cited
US3759890A
Cited
US3850749A
Cited
US3998822A
Cited
US4000137A
Cited
US4041037A
Cited
US4210746A
Cited
US4302533A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-05-06 | 1988-11-05 | 1989-05-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-05-06 | 1992-11-05 | 1993-05-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-05-06 | 1996-11-05 | 1997-05-07 | $7700.00 | Window Closed / Lapsed |